Trial Profile
WEEKLY PEMETREXED (ALIMTA) AND RADIOTHERAPY IN LOCALLY ADVANCED OR LOCALLY RELAPSED NON-SQUAMOUS NON SMALL CELL LUNG CANCERS (NSCLC).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2014
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ALRAD
- 11 Mar 2014 New trial record